Logo

NYS Gives Final Approval for Rosetta Genomics' Thyroid Cancer Test

May 04, 2017 | staff reporter

NEW YORK (GenomeWeb) – Rosetta Genomics today announced New York State has given final approval for the RosettaGx Reveal thyroid cancer test.

The New York State Department of Health had previously provided conditional approval of the microRNA classifier for diagnosing indeterminate thyroid cancer cases. Rosetta's laboratory is CLIA-certified but it required additional licensure from New York in order to receive and process samples for the test from residents in the state.

On Tuesday, the company announced it was realigning its strategy to redirect most of its sales and marketing sources to promote the Reveal test. In preliminary first quarter results, Reveal sales rose 54 percent quarter over quarter. 

Filed under

Regulatory News & FDA Approvals
Molecular Diagnostics
Cancer
regulatory approval
thyroid cancer
New York State Department of Health
miRNA
Rosetta Genomics
Breaking News
The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.